BPC-157 vs Thymosin beta-4
A peptide sold to heal tendons, muscles and the gut. It has been tested mostly in rats, and the only human report covers 12 patients. It is sold as an injection to heal tendon, muscle and joint injuries. No one has tested that use in people; the small human trials are on eye drops, the heart and safety.
Thymosin beta-4 has the stronger evidence, grade B (some human evidence) against grade C for BPC-157. Neither is FDA approved.
Evidence
CAnimal and cell studies
BSome human evidence
Human studies cited
Animal or cell studies cited
Why the grade
A 2025 systematic review found 36 studies of BPC-157 for musculoskeletal injury: 35 preclinical, almost all in rats from one Zagreb research group, and one retrospective human series of 12 patients with knee pain. No randomized or controlled human trial has been published, so the healing claims rest on animal data (grade C). A second review, searching to June 2026, found nothing new.
Thymosin beta-4 has two phase 1 safety trials in healthy volunteers (40 and 84 subjects), an 18-patient phase 3 eye-drop trial, a 96-patient randomized trial after heart attack, and a venous ulcer study. All are small and most tested topical or intravenous full-length protein for specific diseases, not the injected wound-healing use it is sold for. Animal work in rats and mice supports wound and cardiac effects. Grade B for the clinical indications under study; the injury-recovery use sold online has no trial.
FDA
Not approved
BPC-157 is not approved by the FDA for any use and is sold as a research chemical. On 28 October 2026 HHS issued an enforcement discretion policy. Under it, HHS will not act against state-licensed pharmacies and physicians that compound BPC-157 acetate for a named patient, by injection, by mouth or on the skin, if they meet sourcing, testing, labeling and reporting conditions. The policy is not an approval and does not add BPC-157 to the 503A bulks list. It lasts until a final rule settles that question.
Not approved
Thymosin beta-4 is not approved by the FDA for any use. Injectable products sold online, often labeled TB-500 (which the FDA reviewed as a seven-amino-acid fragment), are research chemicals; the FDA found no human exposure data for TB-500, and the agency has not acted on its compounding advisory committee's July 2026 vote to recommend adding TB-500 to the 503A bulks list. RGN-259 eye drops are in a phase 3 trial for neurotrophic keratopathy, and a recombinant intravenous form has been tested in heart attack patients.
Sold for
BPC-157 is sold as a healing peptide for tendons, ligaments, muscle and gut, taken by injection or orally, and is one of the most popular compounds in the grey-market peptide trade.
Thymosin beta-4 is sold as a regenerative injection for tendon, muscle and joint injuries and promoted as the full-length version of TB-500.
Studies say
Dozens of rat studies, nearly all from one laboratory, show faster tendon, ligament and gut healing, but the only human data are a 12-patient uncontrolled series, so nothing is established in people (grade C).
Small randomized trials show safety and signals of benefit in eye and heart disease, but the injected use for sports injuries has never been tested in people, which is why it grades B for the studied indications and no better.
Class
Synthetic pentadecapeptide (gastric-derived)
Actin-regulating peptide
Route
Several routes
Several routes